Oncocyte (NASDAQ:IMDX) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Oncocyte (NASDAQ:IMDX) from a sell rating to a hold rating in a research report sent to investors on Saturday.

Several other brokerages have also recently issued reports on IMDX. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a report on Friday, March 27th. Lake Street Capital raised their target price on shares of Oncocyte from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $12.00.

Oncocyte Stock Down 0.2%

Shares of IMDX stock opened at $6.41 on Friday. Oncocyte has a 12-month low of $2.33 and a 12-month high of $8.51. The stock has a 50 day moving average of $4.21. The stock has a market capitalization of $206.98 million, a PE ratio of -4.33 and a beta of 1.63.

Oncocyte (NASDAQ:IMDX) last issued its earnings results on Wednesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million for the quarter.

Insider Buying and Selling at Oncocyte

In other Oncocyte news, major shareholder Broadwood Partners, L.P. purchased 280,381 shares of the company’s stock in a transaction dated Thursday, April 23rd. The shares were acquired at an average price of $3.50 per share, for a total transaction of $981,333.50. Following the purchase, the insider directly owned 12,395,081 shares of the company’s stock, valued at $43,382,783.50. The trade was a 2.31% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have acquired 753,045 shares of company stock worth $2,685,120. Company insiders own 2.05% of the company’s stock.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.